Table 1 Baseline characteristics.
Subject | |||||
|---|---|---|---|---|---|
001 | 002 | 003 | 004 | 005 | |
Treatment | AAV1/SERCA2a | AAV1/SERCA2a | AAV1/SERCA2a | Placebo | AAV1/SERCA2a |
Strata | AAV −ve | AAV +ve | AAV −ve | AAV −ve | AAV −ve |
Age (Years) | 36 | 69 | 29 | 49 | 30 |
Sex | M | M | M | M | F |
Ethnicity | White | White | White | Black | White |
BMI | 21.45 | 23.20 | 27.07 | 34.25 | 23.46 |
Cause of Heart Failure | Valvular Heart Disease | Dilated cardiomyopathy | Familial cardiomyopathy | Dilated cardiomyopathy | Familial cardiomyopathy |
Type of LVAD | Heartware HVAD | Heartware HVAD | Thoratec Heartmate 2 | Heartware HVAD | Heartware HVAD |
Duration of Optimal HF Regime (months) | 1 | 19 | 3 | 27 | 14 |
Cardiac Transplant Waiting List? | Yes | Yes | Yes | Yes | Yes |
Creatinine (umol/L) | 62 | 81 | 130 | 128 | 70 |
6MWT (metres) | 623 | 627 | 480 | 563 | 397 |
Peak VO2 (ml/kg/min) | 28.30 | 19.60 | 20.30 | 13.50 | 15.60 |
